关键词：多发性硬化症(MS)；强管道药物分子；中枢神经系统；遗传；环境因素
摘 要：The Global MS market is expected to grow at a steady pace during the period 2012-2016. In 2012, the market was dominated by the Americas, which was followed by the EMEA region and the APAC region. At present, the major portion of the market growth is derived from sales of the best-selling drug, Biogen's Avonex, which is used to treat relapsing forms of MS. Currently, there is no therapy that cures MS completely. Nevertheless, there are a number of therapies that may aid in mitigating the disease by reducing the severity of attacks as well as their frequency. Owing to the low treatment-seeking rate, the low diagnosis rate, and the availability of alternate options, the Global MS market is expected to grow at a steady pace during the forecast period. The new entrants that are expected to enter the market during the forecast period might capture a significant share in the market as the pipeline drugs focus on disease progression. The Global MS market is expected to grow at a CAGR of 3.16 percent during the forecast period.
目 录：01. Executive Summary

02. List of Abbreviations

03. Introduction

04. Market Research Methodology

Market Research Process

Research Design

Research Methodology

05. Scope of the Report

Market Overview

Product Offerings

06. Market Landscape

06.1 Global MS Market

Market Size and Forecast

06.2 MS Market in the US

Market Size and Forecast

06.3 MS Market in Europe

Market Size and Forecast

06.4 Five Forces Analysis

07. Geographical Segmentation

08. Rate of Incidence and Prevalence

09. Vendor Landscape

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Vendor Analysis

16.1 Bayer HealthCare AG

Business Overview

Key Information

SWOT Analysis

16.2 Biogen Idec Inc.

Business Overview

Key Information

SWOT Analysis

16.3 Merck Serono S.A.

Business Overview

Key Information

SWOT Analysis

16.4 Novartis AG

Business Overview

Key Information

SWOT Analysis

16.5 Teva Pharmaceutical Industries Ltd.

Business Overview

Key Information

SWOT Analysis

17. Other Reports in this Series